Cardiac Biomarker Monitoring

About GlucoSentient

GlucoSentient is a privately-held, pre-revenue biotech company developing a novel diagnostic platform that transforms standard blood glucose meters into multi-analyte testing devices. Its core technology translates the presence of non-glucose targets—such as proteins, small molecules, and nucleic acids—into a glucose signal that can be read by any commercially available glucose meter. The company is targeting significant unmet needs in home-based therapeutic drug monitoring and chronic disease management, with initial grant-funded programs focused on monitoring transplant patients, phenylketonuria (PKU), and bipolar disorder. Backed by over $2 million in SBIR grants and led by a team with deep expertise in bioengineering and diagnostics, GlucoSentient aims to democratize access to frequent, quantitative biomarker testing.

Therapeutic Areas